<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 9, 2025</title>
<meta name="color-scheme" content="light dark" />
<style>
  :root { --maxw: 800px; }
  html { -webkit-text-size-adjust: 100%; }
  body { margin: 0; padding: 0; font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji; line-height: 1.6; font-size: 18px; }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

La <span title="management">atención</span> de la diabetes y la obesidad <span title="now uses">ahora utiliza</span> una <span title="risk-based approach">visión de riesgo</span> cardiometabólico-renal (CKM). Las <span title="guidelines">Normas</span> de la ADA <span title="state">indican</span>: <span title="protect">proteger</span> el peso y los órganos, <span title="not just">no solo</span> <span title="control">controlar</span> la HbA1c. Al <span title="choosing">elegir</span> agonistas del receptor GLP-1 (GLP-1RA), tirzepatida o inhibidores de SGLT2, <span title="think about">piense en</span> la <span title="weight loss">pérdida de peso</span> y el <span title="cardiorenal benefit">beneficio cardiorrenal</span>.

1) <span title="For patients with">Para pacientes con</span> obesidad (IMC ≥27–30 kg/m²) y diabetes tipo 2, <span title="without">sin</span> ERC o ECV aterosclerótica mayor: <span title="use">use</span> un incretino potente (tirzepatida o un GLP-1RA de alta eficacia como semaglutida) <span title="early / at an early stage">de forma temprana</span>. <span title="Use it">Úselo</span> <span title="together with">junto con</span> metformina o <span title="after">después de</span> metformina. <span title="Add other medications">Agregue otros medicamentos</span> <span title="if needed">si es necesario</span>.

2) <span title="For people with">Para personas con</span> ECV aterosclerótica o <span title="high risk of">alto riesgo de</span> ECV: <span title="use">use</span> un GLP-1RA <span title="with proven">con beneficio</span> cardiovascular comprobado (semaglutida, dulaglutida, liraglutida). <span title="Use it">Úselo</span> <span title="even if">incluso si</span> la HbA1c <span title="is low">es baja</span> e <span title="even without">incluso sin</span> metformina. <span title="This is based on">Esto se basa en</span> LEADER, SUSTAIN-6, REWIND y SELECT.

3) <span title="In CKD">En ERC</span> (TFGe ≥20 mL/min/1.73 m²) o <span title="heart failure">insuficiencia cardíaca</span>: <span title="start">inicie</span> un inhibidor de SGLT2 <span title="with renal benefit">con beneficio renal</span> y <span title="in heart failure">en insuficiencia cardíaca</span> (empagliflozina, dapagliflozina, canagliflozina u otros <span title="with outcome data">con datos de resultados</span>) <span title="early / at an early stage">de forma temprana</span>.

4) <span title="If there is">Si hay</span> riesgo CKM y obesidad <span title="at the same time">al mismo tiempo</span>: <span title="combine">combine</span> un iSGLT2 <span title="with">con</span> un GLP-1RA o tirzepatida. Los <span title="combination studies">estudios de combinación</span> <span title="show">muestran</span> <span title="additional benefit">beneficio adicional</span> en peso, presión arterial y albuminuria, <span title="without major new safety problems">sin grandes problemas nuevos de seguridad</span>.

5) <span title="Use">Use</span> tirzepatida <span title="instead of">en lugar de</span> GLP-1RA <span title="when you want">cuando desee</span> el <span title="greatest effect">mayor efecto</span> en peso y glucemia, <span title="according to">según</span> SURPASS y SURMOUNT. <span title="Monitor">Vigile</span> los <span title="gastrointestinal effects">efectos gastrointestinales</span> y el <span title="cost or access">costo o acceso</span>.

---
DIALOGUE

Narrator: Hoy, la Dra. Lee <span title="talks with">habla con</span> el Sr. Park <span title="about">sobre</span> el <span title="new management">nuevo manejo</span> de la diabetes y el peso.
Physician: Sr. Park, <span title="you have">usted tiene</span> diabetes tipo 2 y su IMC <span title="is">es</span> 32. Eso <span title="means that">significa que</span> también <span title="you have">tiene</span> obesidad.
Patient: Sí, doctora, <span title="I know that">sé que</span> mi azúcar <span title="is high">está alta</span>. Mi peso <span title="is also a problem">también es un problema</span>.
Physician: <span title="Now we try to">Ahora intentamos</span> <span title="protect">proteger</span> su corazón, riñones y <span title="help with">ayudar con</span> el peso, <span title="not just">no solo</span> <span title="control">controlar</span> el azúcar.
Patient: <span title="How do we do that?">¿Cómo hacemos eso?</span>
Physician: <span title="There are">Hay</span> medicamentos nuevos <span title="called">llamados</span> agonistas del receptor GLP-1, <span title="such as">como</span> semaglutida, o tirzepatida. <span title="They lower">Bajan</span> el azúcar y <span title="help with">ayudan con</span> el peso.
Patient: <span title="Are they safe?">¿Son seguros?</span>
Physician: Sí, <span title="they are safe">son seguros</span> <span title="for most people">para la mayoría de las personas</span>. <span title="They can also">También pueden</span> <span title="reduce your risk">reducir su riesgo</span> de <span title="heart problems">problemas cardíacos</span> y renales.
Patient: <span title="Will I have to">¿Tendré que</span> <span title="stop">dejar</span> la metformina?
Physician: No, <span title="you can take">puede tomar</span> metformina y <span title="add the new medication">agregar el nuevo medicamento</span>. <span title="We can change">Podemos cambiar</span> su plan <span title="if you need">si necesita</span> más ayuda.
Patient: <span title="Is there a better option for me?">¿Hay una mejor opción para mí?</span>
Physician: Tirzepatida <span title="has strong effects">tiene efectos fuertes</span> en peso y azúcar. Semaglutida <span title="also works well">también funciona bien</span>. <span title="We can decide together">Podemos decidir juntos</span>.
Patient: <span title="Thank you, doctor">Gracias, doctora</span>. <span title="I want to try this">Quiero probar esto</span>.
Physician: <span title="Good, we will monitor">Bien, vigilaremos</span> los <span title="side effects">efectos secundarios</span> y <span title="we will make a plan">haremos un plan</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Diabetes and obesity care now use a cardiometabolic–kidney (CKM) risk view. The ADA Standards say: protect weight and organs, not only control HbA1c. When you choose GLP‑1 receptor agonists (GLP‑1RA), tirzepatide, or SGLT2 inhibitors, think about weight loss and cardiorenal benefit.

1) For patients with obesity (BMI ≥27–30 kg/m²) and type 2 diabetes, and no major CKD or ASCVD: use a strong incretin (tirzepatide or high‑efficacy GLP‑1RA like semaglutide) early. Use it with metformin or after metformin. Add other drugs if needed.

2) For people with ASCVD or high ASCVD risk: use a GLP‑1RA with proven CV benefit (semaglutide, dulaglutide, liraglutide). Use it even if HbA1c is low and even without metformin. This is based on LEADER, SUSTAIN‑6, REWIND, and SELECT.

3) In CKD (eGFR ≥20 mL/min/1.73 m²) or heart failure: start an SGLT2 inhibitor with renal and HF benefit (empagliflozin, dapagliflozin, canagliflozin, or others with outcome data) early.

4) If CKM risk and obesity both are present: combine SGLT2i with GLP‑1RA or tirzepatide. Add‑on studies show extra weight, BP, and albuminuria benefit, with no big new safety problems.

5) Use tirzepatide instead of GLP‑1RA when you want the most weight and glycemic effect, based on SURPASS and SURMOUNT. Watch GI effects and cost or access.

---
DIALOGUE

Narrator: Today, Dr. Lee talks to Mr. Park about new diabetes and weight care.
Physician: Mr. Park, you have type 2 diabetes and your BMI is 32. That means you have obesity too.
Patient: Yes, doctor, I know my sugar is high. My weight is also a problem.
Physician: We now try to protect your heart, kidneys, and help with weight, not just control sugar.
Patient: How do we do that?
Physician: There are new medicines called GLP-1 receptor agonists, like semaglutide, or tirzepatide. They lower sugar and help with weight.
Patient: Are they safe?
Physician: Yes, they are safe for most people. They can also lower your risk for heart and kidney problems.
Patient: Will I need to stop metformin?
Physician: No, you can take metformin and add the new medicine. We may change your plan if you need more help.
Patient: Is there a best choice for me?
Physician: Tirzepatide has strong weight and sugar effects. Semaglutide also works well. We can choose together.
Patient: Thank you, doctor. I want to try this.
Physician: Good, we will watch for side effects and make a plan.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 9, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>